Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8SX4

Crystal Structure of eIF4e in complex with Compound 7n

Summary for 8SX4
Entry DOI10.2210/pdb8sx4/pdb
DescriptorEukaryotic translation initiation factor 4E, [(~{Z})-4-[2-azanyl-7-[(5-chloranyl-1~{H}-indol-2-yl)methyl]-6-oxidanylidene-1~{H}-purin-9-yl]but-2-enyl]phosphonic acid, 7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE, ... (4 entities in total)
Functional Keywordseif4e, translation initiation inhibitor, translation
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight45489.72
Authors
Meagher, J.L.,Stuckey, J.A. (deposition date: 2023-05-19, release date: 2023-06-21, Last modification date: 2023-08-23)
Primary citationCardenas, E.L.,O'Rourke, R.L.,Menon, A.,Meagher, J.,Stuckey, J.,Garner, A.L.
Design of Cell-Permeable Inhibitors of Eukaryotic Translation Initiation Factor 4E (eIF4E) for Inhibiting Aberrant Cap-Dependent Translation in Cancer.
J.Med.Chem., 66:10734-10745, 2023
Cited by
PubMed Abstract: Eukaryotic translation initiation factor 4E (eIF4E) is an RNA-binding protein that binds to the mGpppX-cap at the 5' terminus of coding mRNAs to initiate cap-dependent translation. While all cells require cap-dependent translation, cancer cells become addicted to enhanced translational capacity, driving the production of oncogenic proteins involved in proliferation, evasion of apoptosis, metastasis, and angiogenesis, among other cancerous phenotypes. eIF4E is the rate-limiting translation factor, and its activation has been shown to drive cancer initiation, progression, metastasis, and drug resistance. These findings have established eIF4E as a translational oncogene and promising, albeit challenging, anti-cancer therapeutic target. Although significant effort has been put forth toward inhibiting eIF4E, the design of cell-permeable, cap-competitive inhibitors remains a challenge. Herein, we describe our work toward solving this long-standing challenge. By employing an acyclic nucleoside phosphonate prodrug strategy, we report the synthesis of cell-permeable inhibitors of eIF4E binding to capped mRNA to inhibit cap-dependent translation.
PubMed: 37471629
DOI: 10.1021/acs.jmedchem.3c00917
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.986 Å)
Structure validation

249697

PDB entries from 2026-02-25

PDB statisticsPDBj update infoContact PDBjnumon